• DOI:10.1111/j.1463-1326.2009.01188.x
Corpus ID: 23886192

A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

@article{Kipnes2010AOS,
  title={A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes},
  author={M. Kipnes and P. Hollander and K. Fujioka and I. Gantz and T. Seck and N. Erondu and Y. Shentu and K. Lu and S. Suryawanshi and M. Chou and A. Johnson-Levonas and S. Heymsfield and D. Shapiro and K. Kaufman and J. Amatruda},
  journal={Diabetes},
  year={2010},
  volume={12}
}

M. Kipnes, P. Hollander, +12 authors J. Amatruda

Published 2010

Medicine

Diabetes

View on Wiley

onlinelibrary.wiley.com

Save to Library

Create Alert

Cite

Launch Research Feed

Aim: To evaluate the efficacy and safety of taranabant in overweight and obese patients with type 2 diabetes mellitus (T2DM).